Skip to search formSkip to main contentSkip to account menu

Refractory Follicular Lymphoma

Follicular lymphoma grade I, II, III that is resistant to treatment.
National Institutes of Health

Related topics

Related topics

16 relations
Atypical lymphocyteB lymphoblastB-LymphocytesHematopoietic and Lymphoid Cell

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL
EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA… 
2019
2019
RAPID AND DURABLE RESPONSES WITH THE SYK/JAK INHIBITOR CERDULATINIB IN A PHASE 2 STUDY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA—ALONE OR IN COMBINATION WITH RITUXIMAB
treated with the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, intolerance was the most common reason for discontinuation (50… 
2017
2017
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma: Updated results of a phase 1B/2 study.
Scientific support was provided by Grace Ku, MD, of Genentech, Inc. Editorial assistance for this poster was provided by Anne… 
2016
2016
FRESCO: A phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based…
TPS7578Background: Most patients with follicular lymphoma (FL) experience a durable response after initial chemotherapy, however… 
2015
2015
Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab
Three sequential phase II trials were conducted with different immunotherapy approaches to enhance the outcome of autologous… 
2015
2015
Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma
Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL… 
2013
2013
An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.
TPS8614^ Background: Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma (NHL) and comprises approximately 22… 
2013
2013
Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered the only curative treatment for relapsed or… 
2005
2005
Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its…
PURPOSE Standard treatment for relapsed or refractory follicular lymphoma has not been established. Doxorubicin is often given… 
2001
2001
Rituximab in the treatment of refractory follicular lymphoma -- six doses are better than four.
Seventeen patients with refractory follicular lymphoma heavily treated with chemotherapy (>2 regimens), radiotherapy, and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)